Abstract
Adverse events frequently occur with chemotherapy, radiation therapy involving the oral cavity, and hematopoietic stem cell transplantation in cancer treatment. The Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology （MASCC/ISOO） have developed a systematic review methodology and published a updated version of the “MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy” in 2019-2020. In addition, an official Japanese translation of the summary overview was also published. However, because it is an international guideline, some references are made to unapproved drugs or off-label use in Japan. In addition, some parts of the summary outline do not convey the intent derived from the original text. This paper introduces the contents of the revised guideline and details the contents of the summary overview of the guideline with the above-mentioned problems in mind.
